1,4,5,6-tetrahydro-pyrimidin-2-ylamine compounds

US8815881B2 · kind B2 · utility

Assignees

• Hoffmann-La Roche Inc. · US
• SIENA BIOTECH S.P.A. · IT

Inventors

• David Banner · Basel, CH
• Emanuele Gabellieri · Lausanne, CH
• Wolfgang Guba · Memmingen, DE
• Hans Hilpert · Reinach, CH
• Benoit Hornsperger · Altkirch, FR
• Roland Humm · Auggen, DE
• Harald Mauser · Riehen, CH
• Alexander V. Mayweg · Basel, CH
• Robert Narquizian · La Valette-du-Var, FR
• Emmanuel Pinard · Rixheim, FR
• Mark Rogers-Evans · Bottmingen, CH
• Thomas Woltering · Freiburg (Elbe), DE
• Wolfgang Wostl · Weil am Rhein, DE

Key dates

• Filing date: Aug 3, 2011
• Grant date: Aug 26, 2014
• Expiry date: Dec 10, 2031

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61K31/513
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

This invention relates to compounds of the formulawherein R1 to R9 are as described below, or to pharmaceutically acceptable salts thereof. These compounds are BACE2 inhibitors and can be used as medicaments for the therapeutic and/or prophylactic treatment of diseases such as diabetes, particularly type 2 diabetes, and other metabolic disorders.